(MENAFN- PR Newswire) DUBLIN, Oct. 21, 2022 /PRNewswire/ -- The report has been added to ResearchAndMarkets.com's offering.
The global slide stainers market is valued at USD 4.3 billion in 2022 and is projected to reach USD 5.9 billion in 2027 at a CAGR of 6.8% from 2022 to 2027.
The reagents & kits segment accounted for the largest share of the slide stainer market in 2021
The slide stainer market by product is further segmented into the slide stainer market is segmented into reagents & kits, equipment, and consumables & accessories. The reagents & kits dominated the slide stainer products with the high usage of the reagent & kits in the diagnosis and research of various diseases such as cancer, infections and other chronic conditions. The lung pathology-related diagnosis and research-related studies have increased the volume of slide staining.
The hematoxyline & eosin segment accounted for the largest share of the slide stainer market in 2021
The slide stainer market by technology is further segmented into the slide stainer market is segmented into hematoxylin & eosin, immunohistochemistry, in situ hybridization, cytology, microbiology, hematology, and special staining. The hematoxylin & eosin dominated the slide stainer products. Hematoxylin & eosin is the most used slide staining technique used for the diagnosis and research of cancer, infectious, and other chronic diseases.
The disease diagnosis application segment is estimated to grow at a rapid rate during the forecast period
Based on application, the slide stainer market is segmented into disease diagnosis and medical research. In 2021, the disease diagnosis application accounted for the largest share of the slide stainer market and is projected to grow at the highest CAGR. The increasing cases of cancer, such as breast cancer, gastric cancer, lymphoma, etc., and infections. The prevalence of cancer and various infections is rising, which has boosted the growth rate of the application segment.
Hospitals & diagnostics centers segment accounted for the largest share of end-users of the slide stainer market in 2021
The end-user segment of the slide stainer market is further segmented into hospitals and diagnostics centers, academic and research institutes, pharmaceutical and biotechnology companies, and other end-users. The dominant share was accounted for by the hospitals and diagnostics centers segment in 2021, which was driven by the high volume of cancer slide staining due to the cancer biopsies, diagnosis and research. Also, the high burden of infections such as COVID-19 and their diagnosis have promoted the segment of the slide stainer end-users.
Asia-Pacific is the fastest-growing regional market for slide stainer
In 2021, the slide stainer market was further divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America region ruled the market in 2021, followed by Europe. Although, the Asia-Pacific region is expected to grow with the fastest growth rate during the forecast period of 2022 to 2027, with the improving healthcare infrastructure, medical investments, vast patient base of geriatric patients and increasing cases of cancer, infections and other chronic complications.
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights 4.1 Slide Stainer Market Overview4.2 Asia-Pacific Slide Stainer Market: by Application and Country (2021)4.3 Geographic Mix: Slide Stainer Market4.4 Slide Stainer Market: Geographic Snapshot
5 Market Overview 5.1 Introduction5.2 Market Dynamics5.2.1 Drivers5.2.1.1 Rising Prevalence of Cancer5.2.1.2 Recommendations for Cancer Screening5.2.1.3 Increasing Healthcare Expenditure5.2.1.4 Rising Geriatric Population and Subsequent Growth in Chronic and Infectious Disease Prevalence5.2.1.5 Growing Number of Private Diagnostic Centers Globally5.2.1.6 Increasing Automation in Laboratories5.2.1.7 Increasing Use of AI in Histopathology5.2.2 Restraints5.2.2.1 High Equipment Cost5.2.3 Opportunities5.2.3.1 High-Growth Opportunities in Emerging Markets5.2.3.2 Increasing Number of Clinical Trials Pertaining to Cancer Drugs5.2.4 Challenges5.2.4.1 Dearth of Knowledgeable and Skilled Technicians5.2.4.2 Product Recalls5.2.4.3 Availability of Refurbished Equipment5.3 Value Chain Analysis5.4 Supply Chain Analysis5.5 Technology Analysis5.6 Porter's Five Forces Analysis5.6.1 Threat of New Entrants5.6.2 Intensity of Competitive Rivalry5.6.3 Bargaining Power of Buyers5.6.4 Bargaining Power of Suppliers5.6.5 Threat of Substitutes5.7 Key Stakeholders and Buying Criteria5.7.1 Key Stakeholders in Buying Process5.7.2 Buying Criteria5.8 Regulatory Landscape5.9 Patent Analysis5.10 Key Conferences and Events in 2022-20235.11 Pricing Analysis5.12 Trade Analysis5.13 Ecosystem Analysis5.14 Trends/Disruptions Impacting Customers' Businesses
6 Slide Stainer Market, by Product 6.1 Introduction6.2 Reagents and Kits6.2.1 Stains6.2.1.1 Staining is Extensively Used in Diagnosis and Research of Carcinoma Tissue Samples6.2.2 Blocking Sera and Reagents6.2.2.1 Blocking Sera and Reagents Prevent Nonspecific Binding and Reduce Background Noise6.2.3 Diluents and Buffers6.2.3.1 Diluents and Buffers are Used for IHC Workflow Optimization6.2.4 Mounting Media, Fixative Reagents, and Embedding Media6.2.4.1 Fixative Reagents are Used to Immobilize Antigens and Retain Cellular and Subcellular Structures6.2.5 Probes6.2.5.1 Probes are Widely Used in ISH6.2.6 Antibodies6.2.6.1 Increasing Prevalence of Infectious Diseases and Cancer to Drive Segment Growth6.3 Equipment6.3.1 Automated and Semi-Automated Slide Stainers6.3.1.1 High-Throughput Efficacy and Accuracy of Staining Biological Samples Driving Segment Growth6.3.2 Manual Slide Staining Sets6.3.2.1 Low Cost of Manual Staining Sets to Drive Segment Growth6.4 Consumables and Accessories
7 Slide Stainer Market, by Application 7.1 Introduction7.2 Disease Diagnostics7.2.1 Breast Cancer7.2.1.1 High Prevalence of Breast Cancer to Drive Segment Growth7.2.2 Gastric Cancer7.2.2.1 Growing Prevalence of and Increasing Research on Gastric Cancer to Drive Segment Growth7.2.3 Lymphoma7.2.3.1 IHC and Biopsy are Preferable Tests to Diagnose Lymphoma7.2.4 Prostate Cancer7.2.4.1 IHC Tests are Used to Identify Prostate Cancer7.2.5 Non-Small Cell Lung Cancer7.2.5.1 IHC Helps Analyze Adenocarcinoma and Squamous Carcinoma of Lungs Through Staining of Antibodies7.2.6 Other Diseases7.3 Medical Research7.3.1 Wide Use of Tissue Biopsy and Slide Staining in Drug Development to Drive Segment Growth
8 Slide Stainer Market, by Technology 8.1 Introduction8.2 Hematoxylin & Eosin (H&E)8.2.1 Wide Use of H&E for Staining Various Biological Samples Driving Segment Growth8.3 Immunohistochemistry (IHC)8.3.1 Automation of IHC Techniques Driving Segment Growth8.4 In Situ Hybridization (ISH)8.4.1 Emerging ISH Staining Techniques such as FISH and CISH Driving Segment Growth8.5 Cytology8.5.1 Wide Use of Cytology for Cancer Studies Driving Segment Growth8.6 Microbiology8.6.1 Increasing Prevalence of Infectious Diseases Driving Segment Growth8.7 Hematology8.7.1 Increasing Prevalence of Hematology Disorders Driving Segment Growth8.8 Special Staining8.8.1 Special Staining is Used Where Routine H&E Techniques Cannot Provide Needed Information
9 Slide Stainer Market, by End-user 9.1 Introduction9.2 Hospitals and Diagnostic Laboratories9.2.1 Number of Hospitals and Diagnostic Laboratories Increasing in Several Countries9.3 Academic and Research Institutes9.3.1 Increasing Investments for Research on Disease Diagnosis Driving Segment Growth9.4 Pharmaceutical and Biotechnology Companies9.4.1 Increasing Research on Drug Discovery to Drive Segment Growth9.5 Other End-users
10 Slide Stainer Market, by Region
11 Competitive Landscape 11.1 Overview11.2 Key Player Strategies/Right to Win11.3 Revenue Share Analysis11.4 Market Share Analysis11.5 Company Evaluation Matrix11.5.1 Stars11.5.2 Pervasive Players11.5.3 Emerging Leaders11.5.4 Participants11.6 Company Evaluation Matrix for SMEs/Start-Ups11.6.1 Progressive Companies11.6.2 Responsive Companies11.6.3 Starting Blocks11.6.4 Dynamic Companies11.7 Company Footprint Analysis11.7.1 Regional Footprint of Companies11.7.2 Product Footprint of Companies11.7.3 Overall Footprint of Companies11.8 Competitive Benchmarking11.9 Competitive Scenario11.9.1 Product Launches/Approvals11.9.2 Deals11.9.3 Other Developments
12 Company Profiles 12.1 Key Players12.1.1 F. Hoffmann-La Roche Ltd.12.1.2 Danaher12.1.3 PHC Holdings Corporation12.1.4 Merck KGaA12.1.5 Agilent Technologies, Inc.12.1.6 Abcam PLC12.1.7 Becton, Dickinson and Company12.1.8 Siemens Healthineers AG12.1.9 Sakura Finetek Japan Co. Ltd.12.1.10 Biocare Medical, LLC12.1.11 Hardy Diagnostics12.1.12 General Data Company, Inc.12.1.13 ELITechGroup12.1.14 BioGenex12.1.15 Histo-Line Laboratories12.1.16 SLEE Medical GmbH12.1.17 Amos Scientific Pty. Ltd.12.2 Other Players12.2.1 MEDITE Medical GmbH12.2.2 CellPath Ltd.12.2.3 Diapath S.p.A.12.2.4 Bio SB, Inc.12.2.5 Rockland Immunochemicals, Inc.12.2.6 Cell Signaling Technology, Inc.12.2.7 Diagnostic BioSystems, Inc.12.2.8 Dakewe Biotechnology Co. Ltd.12.2.9 Thermo Fisher Scientific, Inc.
13 Appendix
For more information about this report visit
Media Contact:
Research and MarketsLaura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
Comments
No comment